The George Institute For Global Health
Global
United Kingdom
India
China
Australia

QUARTET: A quadruple ultra-low dose treatment for patients with hypertension.

Project status: 
Archived
Start date: 
01/2016
Fact sheet

Aim: To investigate in a double blind randomised controlled trial whether initiating treatment with ultra-low-dose quadruple-combination therapy (‘LDQT’) will lower blood pressure more effectively, and with fewer side effects, compared to initiating standard dose monotherapy as per current guidelines in patients with hypertension.

Methods: A 12-week with option to extend to 12 months, double blind randomised controlled trial comparing ultra-low dose quadruple combination therapy (LDQT) with standard dose irbesartan in participants with grade 1 and 2 essential hypertension. This study is funded by a grant from the National Health and Medical Research Council.